Get started
Author

Shannon L. Winski

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms
2000 · David Ross, Jadwiga K Kepa, et al. · Chemico-Biological Interactions · 628
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
2022 · Jill Hallin, Vickie Bowcut, et al. · Nature Medicine · 572
PDF
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
2017 · Alexander Drilon, Ramamoorthy Nagasubramanian, et al. · Cancer Discovery · 464
Selective RET kinase inhibition for patients with RET-altered cancers
2018 · V. Subbiah, V. Velcheti, et al. · Annals of Oncology · 443
PDF
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H: quinone oxidoreductase 1
1999 · David Siegel, Susan M. McGuinness, et al. · Pharmacogenetics · 242
Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1
2001 · David Siegel, Adil Anwar, et al. · Molecular Pharmacology · 216
Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: Species comparison and structural changes with substrate binding and release
2000 · Margarita Faig, Mario A. Bianchet, et al. · Proceedings of the National Academy of Sciences · 213
PDF
A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
1998 · S L Winski, R H Hargreaves, et al. · PubMed · 108
Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
2002 · Shannon L Winski, Yiannis Koutalos, et al. · PubMed · 105
Interactions of rat red blood cell sulfhydryls with arsenate and arsenite
1995 · Shannon L. Winski, Dean E. Carter · Journal of Toxicology and Environmental Health · 104
Characterization of a Mechanism-Based Inhibitor of NAD(P)H:Quinone Oxidoreductase 1 by Biochemical, X-ray Crystallographic, and Mass Spectrometric Approaches
2001 · Shannon L. Winski, Margarita Faig, et al. · Biochemistry · 96
Arsenate Toxicity in Human Erythrocytes: Characterization of Morphologic Changes and Determination of the Mechanism of Damage
1998 · Shannon L. Winski Dean E. Carter · Journal of Toxicology and Environmental Health · 88
OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models
2006 · Andrew J. Garton, Andrew P.A. Crew, et al. · Cancer Research · 85
PDF
Structure-Based Development of Anticancer Drugs
2001 · Margarita Faig, Mario A. Bianchet, et al. · Structure · 84
PDF
Indolequinone Antitumor Agents: Correlation between Quinone Structure, Rate of Metabolism by Recombinant Human NAD(P)H:Quinone Oxidoreductase, and in Vitro Cytotoxicity
1998 · Howard D. Beall, Shannon Winski, et al. · Journal of Medicinal Chemistry · 83
Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones 1 2 1In accordance with the policy of the University of Colorado Health Sciences Center, D.R., R.H.J.H., and J.B. declare a patent interest in RH1. 2Abbreviations: MMC, mitomycin C; NQO1, NAD(P)H:quinone oxidoreductase 1 or DT-diaphorase; MeDZQ, 2,5-diaziridinyl-3,6-dimethyl-1,4-benzoquinone; DCPIP, 2,6-dichlorophenol-indophenol; MTT, thiazolyl blue; P450R, NADPH:cytochrome P450 reductase; b5R, NADH:cytochrome b5 reductase; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; FBS, fetal bovine serum; and MEM, Eagle’s minimum essential medium.
2001 · Shannon L. Winski, Elizabeth Swann, et al. · Biochemical Pharmacology · 82
A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
2014 · Guillermo Garcia-Manero, Hanna J. Khoury, et al. · Clinical Cancer Research · 56
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia
2016 · Lohith Bachegowda, Kerry Morrone, et al. · Cancer Research · 50
Sequence of Toxic Events in Arsine-Induced Hemolysisin Vitro:Implications for the Mechanism of Toxicity in Human Erythrocytes
1997 · S Winski · Fundamental and Applied Toxicology · 46
Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice
2012 · Victoria Dinkel, Deborah Anderson, et al. · Cancer Research · 45
MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
2022 · Lauren E. Stopfer, Nicholas J. Rettko, et al. · Proceedings of the National Academy of Sciences · 37
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
2010 · Patrice A. Lee, Eli Wallace, et al. · Cancer Research · 37
Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones
2004 · Donna L. Dehn, Shannon L. Winski, et al. · Clinical Cancer Research · 35
Differential Involvement of Caspases in Hydroquinone-Induced Apoptosis in Human Leukemic HL-60 and Jurkat Cells
2001 · Salmaan H. Inayat-Hussain, Shannon L. Winski, et al. · Toxicology and Applied Pharmacology · 34
162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations
2010 · S. Winski, D. Anderson, et al. · European Journal of Cancer Supplements · 28
Works count: 112
Citation count: 4,218
H-index: 25
I10-index: 33
Year
Topic
Type